Programming the magnitude and persistence of antibody responses with innate immunity
- PMID: 21350488
- PMCID: PMC3057367
- DOI: 10.1038/nature09737
Programming the magnitude and persistence of antibody responses with innate immunity
Abstract
Many successful vaccines induce persistent antibody responses that can last a lifetime. The mechanisms by which they do so remain unclear, but emerging evidence indicates that they activate dendritic cells via Toll-like receptors (TLRs). For example, the yellow fever vaccine YF-17D, one of the most successful empiric vaccines ever developed, activates dendritic cells via multiple TLRs to stimulate proinflammatory cytokines. Triggering specific combinations of TLRs in dendritic cells can induce synergistic production of cytokines, which results in enhanced T-cell responses, but its impact on antibody responses remain unknown. Learning the critical parameters of innate immunity that program such antibody responses remains a major challenge in vaccinology. Here we demonstrate that immunization of mice with synthetic nanoparticles containing antigens plus ligands that signal through TLR4 and TLR7 induces synergistic increases in antigen-specific, neutralizing antibodies compared to immunization with nanoparticles containing antigens plus a single TLR ligand. Consistent with this there was enhanced persistence of germinal centres and of plasma-cell responses, which persisted in the lymph nodes for >1.5 years. Surprisingly, there was no enhancement of the early short-lived plasma-cell response relative to that observed with single TLR ligands. Molecular profiling of activated B cells, isolated 7 days after immunization, indicated that there was early programming towards B-cell memory. Antibody responses were dependent on direct triggering of both TLRs on B cells and dendritic cells, as well as on T-cell help. Immunization protected completely against lethal avian and swine influenza virus strains in mice, and induced robust immunity against pandemic H1N1 influenza in rhesus macaques.
Figures




Comment in
-
Vaccines: nano-adjuvant: double TLR stimulation is the key.Nat Rev Drug Discov. 2011 Apr;10(4):258. doi: 10.1038/nrd3426. Nat Rev Drug Discov. 2011. PMID: 21455232 No abstract available.
-
Vaccines: Dual TLR hit for vaccine success.Nat Rev Immunol. 2011 Apr;11(4):234-5. doi: 10.1038/nri2966. Nat Rev Immunol. 2011. PMID: 21553709 No abstract available.
References
-
- Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124:849–863. - PubMed
-
- Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 11:373–384. - PubMed
-
- Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009 - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
- R37 AI048638/AI/NIAID NIH HHS/United States
- U19 AI090023/AI/NIAID NIH HHS/United States
- U01 AI070469/AI/NIAID NIH HHS/United States
- U19AI090023/AI/NIAID NIH HHS/United States
- R01DK057665/DK/NIDDK NIH HHS/United States
- U01AI070469/AI/NIAID NIH HHS/United States
- R56 AI048638/AI/NIAID NIH HHS/United States
- U54AI057157/AI/NIAID NIH HHS/United States
- R37 DK057665/DK/NIDDK NIH HHS/United States
- R01 AI048638/AI/NIAID NIH HHS/United States
- R37AI48638/AI/NIAID NIH HHS/United States
- U19 AI057266/AI/NIAID NIH HHS/United States
- N01 AI050025/AI/NIAID NIH HHS/United States
- R01 DK057665/DK/NIDDK NIH HHS/United States
- U19AI057266/AI/NIAID NIH HHS/United States
- U54AI57158/AI/NIAID NIH HHS/United States
- N01 AI50025/AI/NIAID NIH HHS/United States
- U54 AI057157/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases